


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-BB9F33F9-3399-4A4E-9075-8350FD744EAD_4_en-US
DOI: https://doi.org/10.31003/USPNF_M48030_04_01
DOI Ref: cx7ic

© 2025 USPC
Do not distribute

Mefenamic Acid



$C_{15}H_{15}NO_2$ 241.29

Benzoic acid, 2-(2,3-dimethylphenyl)amino-

N-2,3-Xylylanthranilic acid CAS RN®: 61-68-7; UNII: 367589PJ2C.

DEFINITION

Mefenamic Acid contains NLT 98.0% and NMT 102.0% of mefenamic acid ($C_{15}H_{15}NO_2$), calculated on the dried basis.

IDENTIFICATION

- A. **SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy**: 197K or 197A▲ (CN 1-May-2020)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 50 mM [monobasic ammonium phosphate](#). Adjust with 3 M [ammonium hydroxide](#) to a pH of 5.0.

Mobile phase: [Acetonitrile](#), [tetrahydrofuran](#), and *Buffer* (23:7:20)

Standard solution: 0.2 mg/mL of [USP Mefenamic Acid RS](#) in *Mobile phase*

Sample solution: 0.2 mg/mL of Mefenamic Acid in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Column efficiency: NLT 8200 theoretical plates

Tailing factor: NMT 1.6

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of mefenamic acid ($C_{15}H_{15}NO_2$) in the portion of Mefenamic Acid taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of mefenamic acid from the *Sample solution*

r_s = peak response of mefenamic acid from the *Standard solution*

C_s = concentration of [USP Mefenamic Acid RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Mefenamic Acid in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

- **RESIDUE ON IGNITION (281)**: NMT 0.1%

- **ORGANIC IMPURITIES**

Buffer, Mobile phase, and Chromatographic system: Proceed as directed in the Assay.

Standard solution: 0.01 mg/mL of [USP Mefenamic Acid RS](#) in *Mobile phase*

Sensitivity solution: 0.3 µg/mL of [USP Mefenamic Acid RS](#) in *Mobile phase* from the *Standard solution*

Sample solution: 1 mg/mL of Mefenamic Acid in *Mobile phase*

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 1.6, *Standard solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Mefenamic Acid taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of each impurity from the *Sample solution*

r_s = peak response of mefenamic acid from the *Standard solution*

C_s = concentration of [USP Mefenamic Acid RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Mefenamic Acid in the *Sample solution* (mg/mL)

Acceptance criteria: The reporting threshold is 0.03%.

Any impurity: NMT 0.07%

Total impurities: NMT 0.5%

SPECIFIC TESTS

- [LOSS ON DRYING \(731\)](#)

Analysis: Dry at 105° for 4 h.

Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

- [PACKAGING AND STORAGE:](#) Preserve in tight, light-resistant containers.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Mefenamic Acid RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MEFENAMIC ACID	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(5)

Current DocID: [GUID-BB9F33F9-3399-4A4E-9075-8350FD744EAD_4_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M48030_04_01

DOI ref: [ex7ic](#)